Paras Healthcare Approves Unaudited Financial Results for Q2 FY27 and Director Continuation
Paras Healthcare's Board approved unaudited financial results for Q2 FY27. They also approved the continuation of Mr. Kabir Kishin Thakur as a Non-Executive Non-Independent Director, pending shareholder approval. Mr. Thakur has extensive experience in investment and private equity.
The approval of financial results is a routine but important update. The continuation of a director, pending shareholder approval, is a significant governance-related decision that impacts the board structure.
The approval of financial results and the continuation of a director are positive developments for the company.
Paras Healthcare Limited announced the outcome of its Board Meeting held on November 05, 2026. The Board, based on the recommendations of the Audit Committee, considered and approved the Unaudited (Standalone and Consolidated) Financial Results for the quarter and half year ended September 30, 2026. The Limited Review Reports issued by M/s. Walker Chandiok & Co LLP, Chartered Accountants, were also approved and enclosed with the results.
Furthermore, the Board, acting on the recommendations of the Nomination and Remuneration Committee, approved the continuation of Mr. Kabir Kishin Thakur as a Non-Executive Non-Independent Director. This continuation is subject to the approval of the Company's Shareholders and is in accordance with Regulation 17(1D) of the SEBI Listing Regulations. Mr. Thakur is not debarred from holding office by any SEBI order or other authority. His brief profile indicates over 19 years of experience in investment and private equity, having previously been associated with ChrysCapital Group and Citibank's investment banking division. He is currently a designated partner at CR Advisors LLP and Creador Conscienta LLP. He is not related to any other Directors of the Company.
The Board meeting commenced at 05:30 P.M. (IST) and concluded at 06:08 P.M. (IST). This disclosure will be hosted on the Company’s website at https://www.parashospitals.com/investors.
What to do with a filing like this
Paras Healthcare Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Paras Healthcare Limited. Read the original for the full detail.